Patents by Inventor Michael Sloane

Michael Sloane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11202755
    Abstract: By individually metering and dispensing specific volumes and/or weights of each component of a dosage, an amount of the components for each dose is secured with very high accuracy. A method for dosing a pharmaceutical product in a sealed container, such as, for example, a packet, sachet, blister pack, or other unit dose form. The dosage may include a first component that is a thickening agent and a second component that is an active ingredient. The thickening agent serves as a carrier that allows the active ingredient to dissolve in the mouth and be swallowed without the administration of water. The method includes providing the first component by measuring the volume or weighing the mass of the first component and measuring the volume or weighing the mass of the second component. Subsequent components may also be individually measured or weighed before being added to a package.
    Type: Grant
    Filed: February 21, 2016
    Date of Patent: December 21, 2021
    Assignee: UniWell Laboratories, LLC
    Inventors: Alan Jones, Cesar Rodriguez, David Henzler, Jeff Currington, Megha Sharma, Daniel Aldrich, Cameron Currington, Michael Sloane
  • Publication number: 20180177719
    Abstract: By individually metering and dispensing specific volumes and/or weights of each component of a dosage, an amount of the components for each dose is secured with very high accuracy. A method for dosing a pharmaceutical product in a sealed container, such as, for example, a packet, sachet, blister pack, or other unit dose form. The dosage may include a first component that is a thickening agent and a second component that is an active ingredient. The thickening agent serves as a carrier that allows the active ingredient to dissolve in the mouth and be swallowed without the administration of water. The method includes providing the first component by measuring the volume or weighing the mass of the first component and measuring the volume or weighing the mass of the second component. Subsequent components may also be individually measured or weighed before being added to a package.
    Type: Application
    Filed: February 21, 2016
    Publication date: June 28, 2018
    Inventors: Alan Jones, Cesar Rodriguez, David Henzler, Jeff Currington, Megha Sharma, Daniel Aldrich, Cameron Currington, Michael Sloane
  • Patent number: 9057675
    Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: June 16, 2015
    Assignee: NEOS THERAPEUTICS, LP
    Inventors: Russell McMahen, Mark Tengler, Michael Sloane, Daniel Lockhart
  • Publication number: 20140033806
    Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.
    Type: Application
    Filed: May 29, 2013
    Publication date: February 6, 2014
    Applicant: NEOS THERAPEUTICS, LP
    Inventors: Russell McMAHEN, Mark Tengler, Michael Sloane, Daniel Lockhart
  • Patent number: 8512759
    Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: August 20, 2013
    Assignee: Neos Therapeutics, LP
    Inventors: Russell McMahen, Mark Tengler, Michael Sloane, Daniel Lockhart
  • Patent number: 8470375
    Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: June 25, 2013
    Assignee: NEOS Therapeutics, LP
    Inventors: Russell McMahen, Mark Tengler, Michael Sloane, Daniel Lockhart